BR112015022762A2 - composto éster de ácido guanidino benzóico - Google Patents

composto éster de ácido guanidino benzóico

Info

Publication number
BR112015022762A2
BR112015022762A2 BR112015022762A BR112015022762A BR112015022762A2 BR 112015022762 A2 BR112015022762 A2 BR 112015022762A2 BR 112015022762 A BR112015022762 A BR 112015022762A BR 112015022762 A BR112015022762 A BR 112015022762A BR 112015022762 A2 BR112015022762 A2 BR 112015022762A2
Authority
BR
Brazil
Prior art keywords
acid ester
benzoic acid
ester compound
agent
prevention
Prior art date
Application number
BR112015022762A
Other languages
English (en)
Other versions
BR112015022762B1 (pt
BR112015022762A8 (pt
Inventor
Fujiyasu Jiro
Kaneko Osamu
Sasamura Satoshi
Yamaki Susumu
Satou Tomohki
Imaizumi Tomoyoshi
Asano Toru
Urano Yasuharu
Koike Yuka
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112015022762A2 publication Critical patent/BR112015022762A2/pt
Publication of BR112015022762A8 publication Critical patent/BR112015022762A8/pt
Publication of BR112015022762B1 publication Critical patent/BR112015022762B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo “composto éster de ácido guanidino benzóico” [problema] fornecer um composto que seja útil como um agente para a pre-venção e / ou tratamento de doenças renais. [meios para solução] os presentes inventores estudaram compostos com uma atividade inibidora de tripsina, e confirmaram que um composto de éster de ácido guanidino benzóico tem uma atividade inibidora de tripsina, completando as-sim a presente invenção. o composto de éster de ácido guanidino benzóico da pre-sente invenção pode ser utilizado como um agente para a prevenção e / ou trata-mento de doenças renais (por exemplo, doença renal crônica, nefrite aguda, insufi-ciência renal aguda, e semelhantes) como um agente que irá substituir a terapêuti-ca com dieta de baixa proteína, e / ou como um agente para a prevenção e / ou tra-tamento de doenças relacionadas com a tripsina (por exemplo, pancreatite crônica, doença do refluxo gastroesofágico, encefalopatia hepática, gripe, e semelhantes).
BR112015022762-7A 2013-03-13 2014-03-13 Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto BR112015022762B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-050011 2013-03-13
JP2013050011 2013-03-13
PCT/JP2014/056601 WO2014142219A1 (ja) 2013-03-13 2014-03-13 グアニジノ安息香酸エステル化合物

Publications (3)

Publication Number Publication Date
BR112015022762A2 true BR112015022762A2 (pt) 2017-07-18
BR112015022762A8 BR112015022762A8 (pt) 2018-01-23
BR112015022762B1 BR112015022762B1 (pt) 2022-08-16

Family

ID=51536870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022762-7A BR112015022762B1 (pt) 2013-03-13 2014-03-13 Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto

Country Status (30)

Country Link
US (1) US9969709B2 (pt)
EP (1) EP2975023B1 (pt)
JP (1) JP6314129B2 (pt)
KR (1) KR102145649B1 (pt)
CN (1) CN105051008B (pt)
AU (1) AU2014230583B2 (pt)
BR (1) BR112015022762B1 (pt)
CA (1) CA2905606C (pt)
CY (1) CY1120552T1 (pt)
DK (1) DK2975023T3 (pt)
ES (1) ES2684045T3 (pt)
HK (1) HK1216246A1 (pt)
HR (1) HRP20181371T1 (pt)
HU (1) HUE039526T2 (pt)
IL (1) IL241541B (pt)
LT (1) LT2975023T (pt)
MX (1) MX2015012604A (pt)
MY (1) MY194604A (pt)
PH (1) PH12015502023B1 (pt)
PL (1) PL2975023T3 (pt)
PT (1) PT2975023T (pt)
RS (1) RS57568B1 (pt)
RU (1) RU2661895C2 (pt)
SG (2) SG10201707504VA (pt)
SI (1) SI2975023T1 (pt)
TR (1) TR201809418T4 (pt)
TW (1) TWI666196B (pt)
UA (1) UA118668C2 (pt)
WO (1) WO2014142219A1 (pt)
ZA (1) ZA201506745B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051008B (zh) 2013-03-13 2018-05-29 武田药品工业株式会社 胍基苯甲酸酯化合物
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) * 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
WO2016158788A1 (ja) * 2015-03-27 2016-10-06 武田薬品工業株式会社 縮合複素環化合物
CN105218289B (zh) * 2015-10-15 2017-08-01 浙江大学 一种不饱和脂肪酸原位加氢脱羧制备长链烷烃的方法
BR112020008676A2 (pt) 2017-11-02 2020-10-27 Ube Industries, Ltd. composto, e, composição farmacêutica.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en) * 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
EP0673924A4 (en) 1992-12-10 1996-04-24 Teikoku Chem Ind Co Ltd PROPRIONIC ACID DERIVATIVE.
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
JPH09124571A (ja) * 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
KR20000005312A (ko) * 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
EP1815865A4 (en) 2004-11-08 2010-08-25 Ono Pharmaceutical Co THERAPEUTIC AGENT AGAINST DIABETES WITH A PROTEASE-INHIBITING COMPOUND
EP1843819A2 (en) 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
EP1811865B1 (en) 2004-11-26 2008-07-16 N.V. Nutricia Infant nutrition with protease inhibitor
JP2008528628A (ja) 2005-01-31 2008-07-31 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性二環式化合物
EP1973405A4 (en) 2006-01-12 2011-06-01 Merck Sharp & Dohme HYDROXYALKYMARYLAMIDE DERIVATIVES
PT2225261E (pt) 2007-12-03 2016-06-09 Obe Therapy Biotechnology Inibidores boropeptídicos de enteropeptidase e suas utilizações no tratamento de obesidade, excesso de peso e/ou doenças associadas com um metabolismo anormal da gordura
ES2532201T3 (es) * 2009-12-07 2015-03-25 Ajinomoto Co., Inc. Derivado de éster de ácido heteroarilcarboxílico
JP5959116B2 (ja) 2011-06-07 2016-08-02 Ｅａファーマ株式会社 ヘテロ環カルボン酸エステル誘導体
MX362948B (es) 2011-09-15 2019-02-27 Astellas Pharma Inc Compuesto del ácido guanidinobenzoico.
EP2800579B1 (en) 2012-01-03 2017-08-30 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP4215205A1 (en) 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
CN105051008B (zh) 2013-03-13 2018-05-29 武田药品工业株式会社 胍基苯甲酸酯化合物
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
MX2015012604A (es) 2016-10-13
EP2975023B1 (en) 2018-05-30
HUE039526T2 (hu) 2019-01-28
US9969709B2 (en) 2018-05-15
KR102145649B1 (ko) 2020-08-18
SI2975023T1 (sl) 2018-10-30
TW201522291A (zh) 2015-06-16
JP6314129B2 (ja) 2018-04-18
AU2014230583A1 (en) 2015-10-01
EP2975023A1 (en) 2016-01-20
SG11201507411TA (en) 2015-10-29
LT2975023T (lt) 2018-08-10
KR20150130392A (ko) 2015-11-23
SG10201707504VA (en) 2017-10-30
US20160031847A1 (en) 2016-02-04
RS57568B1 (sr) 2018-10-31
HK1216246A1 (zh) 2016-10-28
CA2905606A1 (en) 2014-09-18
PL2975023T3 (pl) 2018-11-30
TR201809418T4 (tr) 2018-07-23
RU2661895C2 (ru) 2018-07-23
UA118668C2 (uk) 2019-02-25
HRP20181371T1 (hr) 2018-10-19
BR112015022762B1 (pt) 2022-08-16
CA2905606C (en) 2021-03-09
MY194604A (en) 2022-12-06
CN105051008A (zh) 2015-11-11
IL241541B (en) 2019-06-30
BR112015022762A8 (pt) 2018-01-23
EP2975023A4 (en) 2016-08-03
CN105051008B (zh) 2018-05-29
CY1120552T1 (el) 2019-07-10
TWI666196B (zh) 2019-07-21
WO2014142219A1 (ja) 2014-09-18
RU2015143562A (ru) 2017-04-19
JPWO2014142219A1 (ja) 2017-02-16
PH12015502023A1 (en) 2016-01-18
PH12015502023B1 (en) 2016-01-18
PT2975023T (pt) 2018-07-27
AU2014230583B2 (en) 2017-09-28
ZA201506745B (en) 2017-04-26
DK2975023T3 (en) 2018-08-20
ES2684045T3 (es) 2018-10-01

Similar Documents

Publication Publication Date Title
BR112015022762A2 (pt) composto éster de ácido guanidino benzóico
EA201490632A1 (ru) Соединение гуанидинобензойной кислоты
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112014017466A8 (pt) composto de pirazinacarboxamida
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112012002134B8 (pt) compostos inibidores de apaf-1
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112012025390B8 (pt) Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo
BR112018004249A2 (pt) composto, e, composição para prevenção ou tratamento de doenças trombóticas.
BR112018005811A2 (pt) composição farmacêutica para administração na mucosa nasal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2014, OBSERVADAS AS CONDICOES LEGAIS